Abeona Therapeutics Inc. · Nasdaq · Pharmaceutical Preparations
The company reported Q3 2026 net ZEVASKYN revenue of $13.5 million alongside a stock-issuance acquisition of ABO-801 and a private placement at $3.75 per share.
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 29, 2026 | Vishwas Seshadri Chief Executive Officer, director | Sold | 19,608 | $5.16 | $101,091 |
| Sept. 29, 2026 | Joseph Walter Vazzano Chief Financial Officer | Sold | 9,191 | $5.16 | $47,385 |
| Sept. 29, 2026 | Brendan M. O'Malley SVP, Chief Legal Officer | Sold | 6,727 | $5.16 | $34,682 |
| Sept. 29, 2026 | Madhav Vasanthavada Chief Commercial Officer | Sold | 4,902 | $5.16 | $25,273 |
| Sept. 1, 2026 | Mark Alvino director | Sold | 15,000 | $5.86 | $87,966 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedAbeona Therapeutics Q3 2026 revenue of $13.5 million misses $14.8 million consensus, though EPS of -$0.08 beats the -$0.17 estimate on non-operating gains
Entry into a material definitive agreement · Completion of acquisition or disposition of assets · Unregistered sales of equity securities · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedAbeona Therapeutics Acquires APT-1011 (ABO-801) for 4,494,383 Shares and Launches $30 Million Private Placement at $3.75 per Share